We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 29, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Moderna, Inc. (MRNA - Free Report) , Johnson & Johnson (JNJ - Free Report) , Sanofi (SNY - Free Report) and Novavax, Inc. (NVAX - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
3 Stocks to Benefit from Race to Coronavirus Vaccine
The novel coronavirus is wreaking havoc on life and economy, and health care officials and researchers are working relentlessly to find a cure or vaccine. Pharmaceutical companies and scientists are also using artificial intelligence to develop antibody-based drugs. The immense computing power will help scientists to map the genome of the SARS-CoV-2 virus and rework with existing drugs used in the treatment of malaria and Ebola.
As medical companies make progress in coronavirus cure, the stock market, which has been weighed down by closures and lockdowns, has increased slightly. In fact, a rebound in the broader market depends on a viable coronavirus treatment or vaccine.
Progress So Far by Drug Makers
Investors have been closely observing the progress of top pharmaceutical and biotechnology companies as they involve in the development and production of potential COVID-19 remedies. Most companies have so far reported being in pre-clinical or phase 1 stages of trials for their vaccine candidates.
There are more than 70 vaccines in development at present, but the biggest hurdle for researchers is that there are several things they don’t know about the virus. This has left scientists scrambling for every existing solution.
Voltron Therapeutics is working on a COVID-19 vaccine targeting T-cells. The experimental product is moving into animal testing. Some others like Moderna, Inc. and Johnson & Johnson are working on an adenovirus-based vaccine, which is appropriate for faster development, but with speed comes the risk of safety.
Companies at present are making rapid progress in testing, as they receive support from the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases. Moreover, Coalition for Epidemic Preparedness Innovations has been providing millions of dollars in funding vaccine makers.
This could help companies see significant upside if they develop a safe, effective and relatively affordable vaccine soon and lift the broader market in turn. And, why not? The current world population stands at nearly 7.5 billion and given the wide spread of the virus, a vaccine development would help these companies’ shares trend up in no time.
3 Stocks to Watch
We have shortlisted three companies based on their recent progress in coronavirus vaccine development.
On Apr 27, Moderna reported that its candidate for a coronavirus vaccine has received permission to be evaluated further. The company has submitted a new-drug application with the U.S. Food and Drug Administration (FDA) to evaluate the vaccine candidate, mRNA-1273, in a more extensive study if supported by safety data from an initial study. The phase 2 study scheduled to begin soon will evaluate the safety as well as adverse reactions and immune responses of two mRNA-1273 vaccinations given 28 days apart.
Sanofi has joined GlaxoSmithKline to develop a coronavirus vaccine. The company makes the malaria drug hydroxychloroquine, a possible treatment for COVID-19. It is also testing another treatment in partnership with Regeneron.
The company that belongs to the Zacks Large Cap Pharmaceuticals industry has an expected earnings growth rate of 2,4% for the current year.Sanofi carries a Zacks Rank #2 (Buy).
Novavax, Inc. had earlier reported that it was able to identify an antibody which is potentially effective against the SARS-CoV-2 virus that causes COVID-19. Recently, the company reported that it has a vaccine candidate called NVX-CoV2373 that has demonstrated effectiveness against the coronavirus in pre-clinical trials. This Zacks Rank #3 (Hold) company plans to begin human clinical trials in mid-May.
The company’s expected earnings growth rate for the current quarter is 70.5% against the Zacks Medical - Biomedical and Geneticsindustry’s projected earnings decline of more than 100%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax
For Immediate Release
Chicago, IL – April 29, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Moderna, Inc. (MRNA - Free Report) , Johnson & Johnson (JNJ - Free Report) , Sanofi (SNY - Free Report) and Novavax, Inc. (NVAX - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
3 Stocks to Benefit from Race to Coronavirus Vaccine
The novel coronavirus is wreaking havoc on life and economy, and health care officials and researchers are working relentlessly to find a cure or vaccine. Pharmaceutical companies and scientists are also using artificial intelligence to develop antibody-based drugs. The immense computing power will help scientists to map the genome of the SARS-CoV-2 virus and rework with existing drugs used in the treatment of malaria and Ebola.
As medical companies make progress in coronavirus cure, the stock market, which has been weighed down by closures and lockdowns, has increased slightly. In fact, a rebound in the broader market depends on a viable coronavirus treatment or vaccine.
Progress So Far by Drug Makers
Investors have been closely observing the progress of top pharmaceutical and biotechnology companies as they involve in the development and production of potential COVID-19 remedies. Most companies have so far reported being in pre-clinical or phase 1 stages of trials for their vaccine candidates.
There are more than 70 vaccines in development at present, but the biggest hurdle for researchers is that there are several things they don’t know about the virus. This has left scientists scrambling for every existing solution.
Voltron Therapeutics is working on a COVID-19 vaccine targeting T-cells. The experimental product is moving into animal testing. Some others like Moderna, Inc. and Johnson & Johnson are working on an adenovirus-based vaccine, which is appropriate for faster development, but with speed comes the risk of safety.
Companies at present are making rapid progress in testing, as they receive support from the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases. Moreover, Coalition for Epidemic Preparedness Innovations has been providing millions of dollars in funding vaccine makers.
This could help companies see significant upside if they develop a safe, effective and relatively affordable vaccine soon and lift the broader market in turn. And, why not? The current world population stands at nearly 7.5 billion and given the wide spread of the virus, a vaccine development would help these companies’ shares trend up in no time.
3 Stocks to Watch
We have shortlisted three companies based on their recent progress in coronavirus vaccine development.
On Apr 27, Moderna reported that its candidate for a coronavirus vaccine has received permission to be evaluated further. The company has submitted a new-drug application with the U.S. Food and Drug Administration (FDA) to evaluate the vaccine candidate, mRNA-1273, in a more extensive study if supported by safety data from an initial study. The phase 2 study scheduled to begin soon will evaluate the safety as well as adverse reactions and immune responses of two mRNA-1273 vaccinations given 28 days apart.
The company’s expected earnings growth rate for the current quarter is 7.5% against the Zacks Medical - Biomedical and Genetics industry’s projected earnings decline of more than 100%. Moderna flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sanofi has joined GlaxoSmithKline to develop a coronavirus vaccine. The company makes the malaria drug hydroxychloroquine, a possible treatment for COVID-19. It is also testing another treatment in partnership with Regeneron.
The company that belongs to the Zacks Large Cap Pharmaceuticals industry has an expected earnings growth rate of 2,4% for the current year.Sanofi carries a Zacks Rank #2 (Buy).
Novavax, Inc. had earlier reported that it was able to identify an antibody which is potentially effective against the SARS-CoV-2 virus that causes COVID-19. Recently, the company reported that it has a vaccine candidate called NVX-CoV2373 that has demonstrated effectiveness against the coronavirus in pre-clinical trials. This Zacks Rank #3 (Hold) company plans to begin human clinical trials in mid-May.
The company’s expected earnings growth rate for the current quarter is 70.5% against the Zacks Medical - Biomedical and Geneticsindustry’s projected earnings decline of more than 100%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.